Display options
Cite
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2020;39(2):208-221doi: 10.5534/wjmh.200010.
Tak, Y. J., & Lee, S. Y. (2021). Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. The world journal of men's health, 39(2), 208-221. https://doi.org/10.5534/wjmh.200010
Tak, Young Jin, and Lee, Sang Yeoup. "Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review." The world journal of men's health vol. 39,2 (2021): 208-221. doi: https://doi.org/10.5534/wjmh.200010
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2021 Apr;39(2):208-221. doi: 10.5534/wjmh.200010. Epub 2020 Mar 09. PMID: 32202085; PMCID: PMC7994651.
Copy Download .nbib Format: NLM
Share it on

World J Mens Health. 2021 Apr;39(2):208-221. doi: 10.5534/wjmh.200010. Epub 2020 Mar 09.

Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.

The world journal of men's health

Young Jin Tak, Sang Yeoup Lee

Affiliations

  1. Department of Family Medicine, Pusan National University School of Medicine, Yangsan, Korea.
  2. Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  3. Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
  4. Department of Medical Education, Pusan National University School of Medicine, Yangsan, Korea. [email protected].

PMID: 32202085 PMCID: PMC7994651 DOI: 10.5534/wjmh.200010

Abstract

As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically significant weight loss. Increasing evidence has shown that behavior-based interventions with one of these medications can result in greater weight loss than that elicited by usual care conditions. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). However, they have a high cost and may cause adverse outcomes depending on the individual. Very recently, on February 13, 2020, the US Food and Drug Administration requested withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. Therefore the decision to initiate drug therapy in obese individuals should be made after the benefits and risks are considered. Thereafter, treatment should be tailored to specific patient subpopulations depending on their chronic conditions, comorbidities, and preferences. Herein, we provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control.

Copyright © 2021 Korean Society for Sexual Medicine and Andrology.

Keywords: Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Phentermine/topiramate

Conflict of interest statement

The authors have nothing to disclose.

References

  1. Circulation. 2000 Dec 5;102(23):2836-41 - PubMed
  2. Diabetologia. 2016 May;59(5):954-65 - PubMed
  3. Diabetes Obes Metab. 2017 Sep;19(9):1233-1241 - PubMed
  4. World J Mens Health. 2016 Aug;34(2):129-36 - PubMed
  5. Obesity (Silver Spring). 2011 Jan;19(1):110-20 - PubMed
  6. Diabetes Care. 2018 Aug;41(8):1663-1671 - PubMed
  7. JAMA. 2016 Jun 14;315(22):2424-34 - PubMed
  8. Gastroenterology. 2011 Jul;141(1):150-6 - PubMed
  9. Int J Obes Relat Metab Disord. 2002 Mar;26(3):344-53 - PubMed
  10. Endocrinol Metab Clin North Am. 2016 Sep;45(3):xvii-xviii - PubMed
  11. Ann N Y Acad Sci. 2018 Jan;1411(1):106-119 - PubMed
  12. Obes Res. 2000 Dec;8(9):656-63 - PubMed
  13. Diabetes. 2013 Jul;62(7):2595-604 - PubMed
  14. Int J Obes (Lond). 2005 Oct;29(10):1168-74 - PubMed
  15. Curr Drug Targets. 2017;18(8):983-993 - PubMed
  16. Lancet. 2010 Aug 21;376(9741):595-605 - PubMed
  17. Expert Rev Clin Pharmacol. 2020 Feb;13(2):183-190 - PubMed
  18. Diabetes Care. 2017 Jul;40(7):839-848 - PubMed
  19. Biochim Biophys Acta. 2014 Mar;1842(3):377-92 - PubMed
  20. Lancet. 2018 Aug 25;392(10148):637-649 - PubMed
  21. Cancer Lett. 2006 Aug 28;240(2):221-4 - PubMed
  22. Int J Obes Relat Metab Disord. 2003 Jan;27(1):103-9 - PubMed
  23. Int J Obes (Lond). 2013 Nov;37(11):1443-51 - PubMed
  24. Int J Obes (Lond). 2016 Sep;40(9):1369-75 - PubMed
  25. Lancet. 2011 Apr 16;377(9774):1341-52 - PubMed
  26. Obes Rev. 2017 Dec;18(12):1377-1385 - PubMed
  27. N Engl J Med. 2013 Oct 10;369(15):1389-91 - PubMed
  28. Postgrad Med. 2018 Mar;130(2):173-182 - PubMed
  29. Metabolism. 2016 Jul;65(7):945-53 - PubMed
  30. Cell Metab. 2015 Mar 3;21(3):379-91 - PubMed
  31. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016 - PubMed
  32. J Clin Invest. 2013 Dec;123(12):4986-91 - PubMed
  33. N Engl J Med. 2015 Jul 2;373(1):11-22 - PubMed
  34. Obesity (Silver Spring). 2015 Aug;23(8):1721-8 - PubMed
  35. J Clin Invest. 2014 Feb;124(2):499-508 - PubMed
  36. Diabetes Care. 2013 Dec;36(12):4022-9 - PubMed
  37. Obesity (Silver Spring). 2016 Sep;24(9):1955-61 - PubMed
  38. Drugs. 2018 Jul;78(11):1113-1132 - PubMed
  39. Diabetes Care. 2017 May;40(5):632-639 - PubMed
  40. Obesity (Silver Spring). 2014 Apr;22(4):1042-9 - PubMed
  41. J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77 - PubMed
  42. Obesity (Silver Spring). 2009 Jan;17(1):30-9 - PubMed
  43. Am J Med. 2016 Aug;129(8):879.e1-6 - PubMed
  44. Eur J Clin Nutr. 2010 Sep;64(9):994-9 - PubMed
  45. J Clin Pharm Ther. 2020 Feb;45(1):35-44 - PubMed
  46. Obesity (Silver Spring). 2016 Nov;24(11):2278-2288 - PubMed
  47. J Psychopharmacol. 2017 Nov;31(11):1503-1508 - PubMed
  48. Am J Clin Nutr. 2012 Feb;95(2):297-308 - PubMed
  49. JAMA. 2015 Aug 18;314(7):687-99 - PubMed
  50. Obesity (Silver Spring). 2012 Feb;20(2):330-42 - PubMed
  51. Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38 - PubMed
  52. Expert Rev Clin Pharmacol. 2020 Jan;13(1):53-64 - PubMed
  53. Obesity (Silver Spring). 2012 Jul;20(7):1426-36 - PubMed
  54. Endocr Pract. 2016 Jul;22 Suppl 3:1-203 - PubMed
  55. Mol Cell Endocrinol. 2015 Feb 15;402:113-9 - PubMed
  56. Int J Obes (Lond). 2014 Jun;38(6):784-93 - PubMed
  57. Obesity (Silver Spring). 2013 May;21(5):935-43 - PubMed
  58. Diabetes Care. 2004 Jan;27(1):155-61 - PubMed
  59. Diabetes Obes Metab. 2017 Nov;19(11):1529-1536 - PubMed
  60. N Engl J Med. 2018 Sep 20;379(12):1107-1117 - PubMed
  61. Diabetes Res Clin Pract. 2007 Jan;75(1):72-80 - PubMed
  62. J Fam Pract. 2016 Jul;65(7 Suppl):S16-23 - PubMed
  63. Circ Cardiovasc Imaging. 2013 Jul;6(4):560-7 - PubMed
  64. Metabolism. 2018 Jan;78:13-42 - PubMed
  65. J Korean Med Sci. 2015 Aug;30(8):1017-24 - PubMed
  66. Diabetologia. 2018 Oct;61(10):2118-2125 - PubMed
  67. P T. 2013 Sep;38(9):525-34 - PubMed
  68. JAMA. 2014 Jan 1;311(1):74-86 - PubMed
  69. Pharmacol Ther. 1998 Sep;79(3):231-57 - PubMed
  70. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62 - PubMed
  71. Asian J Androl. 2014 Mar-Apr;16(2):223-31 - PubMed
  72. Endocrinol Metab (Seoul). 2014 Dec 29;29(4):410-7 - PubMed
  73. Obes Res. 1998 Sep;6 Suppl 2:51S-209S - PubMed
  74. Lancet. 2018 Nov 24;392(10161):2269-2279 - PubMed
  75. Int J Obes (Lond). 2014 May;38(5):689-97 - PubMed
  76. BMC Public Health. 2019 Oct 15;19(1):1293 - PubMed
  77. Diabetes Care. 2018 Mar;41(3):620-622 - PubMed
  78. World J Mens Health. 2019 May;37(2):138-147 - PubMed
  79. Am J Ther. 2009 Jul-Aug;16(4):354-64 - PubMed
  80. BMJ. 2013 Aug 27;347:f5039 - PubMed
  81. Curr Diab Rep. 2018 Aug 31;18(10):92 - PubMed
  82. World J Mens Health. 2019 Jan;37(1):93-98 - PubMed
  83. Diabetes Care. 2016 Feb;39(2):214-21 - PubMed
  84. N Engl J Med. 2010 Jul 15;363(3):245-56 - PubMed

Publication Types